Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases.
Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients.
Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses.
This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
Negatief, positief, neutraal: we zetten een review altijd online. We controleren wel eerst of ’ie voldoet aan onze reviewvoorwaarden en niet nep is. We controleren ook of ’ie is geschreven door iemand die het artikel heeft gekocht via bol.com en zetten dit er dan bij. De controles gebeuren automatisch, al kijken er soms mensen mee. Bol.com betaalt niet voor reviews. Als een reviewer door een andere partij is vergoed, staat dit in de review zelf.
Kies gewenste uitvoering
Bindwijze
: Paperback
Prijsinformatie en bestellen
De prijs van dit product is 181 euro en 68 cent. De meest getoonde prijs is 250 euro en 99 cent. Je bespaart 28%.181
68
Meest getoonde prijs
250,99
Referentieprijs: de meest getoonde niet-promotie prijs aan klanten op bol in de afgelopen 90 dagen.
Bij seizoensgebonden mode artikelen gaat het om de meest getoonde prijs tijdens de eerste 30 dagen dat het artikel op bol.com te koop staat.
Meer informatie
Je bespaart 28%
3 - 4 weken
Levertijd
We doen er alles aan om dit artikel op tijd te bezorgen. Het is echter in een enkel geval mogelijk dat door omstandigheden de bezorging vertraagd is.
Bezorgopties
We bieden verschillende opties aan voor het bezorgen of ophalen van je bestelling. Welke opties voor jouw bestelling beschikbaar zijn, zie je bij het afronden van de bestelling.
